Meeting
2021 ASCO Annual Meeting
Pembrolizumab (pembro) versus placebo (pbo) in patients (pts) with advanced hepatocellular carcinoma (aHCC) previously treated with sorafenib: Updated data from the randomized, phase 3 KEYNOTE-240 study.
Authors
Richard S. Finn
David Geffen School of Medicine at UCLA, Los Angeles, CA
Richard S. Finn , Julien Edeline , Mohamed Bouattour , Ann-Lii Cheng , Stephen Lam Chan , Thomas Yau , Marcelo Garrido , Jennifer J. Knox , Bruno Daniele , Andrew X. Zhu , Valeriy Vladimirovich Breder , Ho Yeong Lim , Sadahisa Ogasawara , Abby B. Siegel , Ahmadur Rahman , Ziwen Wei , Philippe Merle
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Gastrointestinal Cancer—Gastroesophageal, Pancreatic, and Hepatobiliary
Track
Gastrointestinal Cancer—Gastroesophageal, Pancreatic, and Hepatobiliary
Sub Track
Hepatobiliary Cancer
Clinical Trial Registration Number
NCT02702401
Citation
J Clin Oncol 39, 2021 (suppl 15; abstr 4072)
DOI
10.1200/JCO.2021.39.15_suppl.4072
Abstract #
4072
Poster Bd #
Online Only
Abstract Disclosures
Similar Posters
Poster
2022 ASCO Gastrointestinal Cancers Symposium
Pembrolizumab plus best supportive care versus placebo plus best supportive care as second-line therapy in patients in Asia with advanced hepatocellular carcinoma (HCC): Phase 3 KEYNOTE-394 study.
First Author: Shukui Qin
Poster
2022 ASCO Annual Meeting
Health-related quality of life (HRQoL) impact of pembrolizumab (pembro) plus best supportive care (BSC) versus placebo (PBO) plus BSC as second-line (2L) therapy in patients (pts) in Asia with advanced hepatocellular carcinoma (HCC): Phase 3 KEYNOTE-394 study.
First Author: Shukui Qin
Poster
2020 Gastrointestinal Cancers Symposium
Phase III study of pembrolizumab (pembro) versus best supportive care (BSC) for second-line therapy in advanced hepatocellular carcinoma (aHCC): KEYNOTE-240 Asian subgroup.
First Author: Masatoshi Kudo
Poster
2021 Gastrointestinal Cancers Symposium
Landmark analysis of overall survival (OS) by objective response (OR) in previously treated patients (pts) with advanced hepatocellular carcinoma (aHCC): Post-hoc analysis of the randomized, phase III KEYNOTE-240 study.
First Author: Julien Edeline